| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/28/2004 | CN1471512A Gem-substituted ± ¢ ²3 integrin antagonists |
| 01/28/2004 | CN1471511A Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 01/28/2004 | CN1471393A Method for the treatment of neurological and neuropsychological disorders |
| 01/28/2004 | CN1471392A Method for the treatment of neurological and neuropsychological disorders |
| 01/28/2004 | CN1136203C Benzoxazine and penzothiazine derivatives and their use in pharmaceuticals |
| 01/28/2004 | CN1135982C Process for preparing pharmaceutical composition containing N-acyl-2,3-benzodiazepine deriratives |
| 01/28/2004 | CN1135976C Application of cotucine in pharmacy |
| 01/27/2004 | US6683192 Substituted benzo(b)thien compounds useful for modulating proliferation or differentiation of a cell, agonizes hedgehog mediated signal trasnduction with an ed50 of 1mm or less |
| 01/27/2004 | US6683055 Guanidine or amidine termined peptides |
| 01/27/2004 | US6682906 Cloned glutamic acid decarboxylase |
| 01/22/2004 | WO2004007491A1 Azolidinone-vinyl fused-benzene derivatives |
| 01/22/2004 | WO2004007487A1 Crystalline forms |
| 01/22/2004 | WO2004007486A1 Maleate salts |
| 01/22/2004 | WO2004007485A1 Besylate salts |
| 01/22/2004 | WO2004007484A1 Fumarate salts |
| 01/22/2004 | WO2004007457A2 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | WO2004006954A2 Transdermal botulinum toxin compositions |
| 01/22/2004 | WO2004006930A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 01/22/2004 | WO2004006853A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | WO2004006830A2 Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | US20040016013 Achieves widespread distribution, systemic expression and sustained delivery in the animal; oral gene therapy |
| 01/22/2004 | US20040014992 A dichlorobenzylcyanide or a dichlorophenylcyclohexyl acetic acid methyl ester; use as antagonist of serotonin receptor and dopamine, treating attention deficit hyperactivity disorder, Parkinson's disease, nervous system disorders |
| 01/22/2004 | US20040014796 Antiinflammatory agents; rheumatic diseases; antitumor agents |
| 01/22/2004 | US20040014783 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 01/22/2004 | US20040014782 Combination therapy for the treatment of diseases involving inflammatory components |
| 01/22/2004 | US20040014760 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 01/22/2004 | US20040014745 Amide compounds |
| 01/22/2004 | US20040014721 Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 01/22/2004 | US20040014704 Reducing immunology response; sustained release |
| 01/22/2004 | US20040014698 Oral administration of therapeutic agent coupled to transporting agent |
| 01/22/2004 | US20040014111 Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013680 Neurotoxic oligomers |
| 01/22/2004 | US20040013676 Administering dosage of mature dendritic cells in carrier |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492029A1 Transdermal botulinum toxin compositions |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382347A1 Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381630A2 Vhh single heavy chain antibody and a method for its preparation in a mammal |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381369A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence |
| 01/21/2004 | EP1381363A1 Imidazo [1,2-a]-pyridine derivatives as mglur5 antagonists |
| 01/21/2004 | EP0942723B1 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| 01/21/2004 | CN1469866A New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl- pyrimidines, their preparation and application as medication |
| 01/20/2004 | US6680330 Rapamycin dialdehydes |
| 01/20/2004 | US6680328 Cholinergic ligands of nicotinic acetyl choline receptors for treatment of central nervous system disorders, smooth muscle contraction disorders, endocrine diseases/disorders, neurodegeneration, inflammation, pain, and drug withdrawal |
| 01/20/2004 | US6680317 N-(phenyl)-n*-(2-hydroxy-3-aminosulfonylphenyl)guanidine derivatives; chemokine inhibitors; respiratory, cardiovascular, rheumatic, brain, and nervous system disorders |
| 01/20/2004 | US6680314 Azacyclooctane and heptane derivatives, their preparation and use in therapy |
| 01/20/2004 | CA2308745C 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]hydrohalogenides |
| 01/20/2004 | CA2303498C Dioxocyclopentyl hydroxamic acids |
| 01/15/2004 | WO2004005510A1 NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF |
| 01/15/2004 | WO2004005494A1 Medium for culturing autologous human progenitor stem cells and applications thereof |
| 01/15/2004 | WO2004005313A2 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 01/15/2004 | WO2004005309A2 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004763A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | WO2004004720A1 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
| 01/15/2004 | WO2004004656A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | WO2003092608A3 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003084936A8 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 01/15/2004 | WO2003082216A3 Neuroprotectant methods, compositions, and screening methods thereof |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003079969A3 Compositions and methods for treating and preventing necrosis |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002080966A8 Method for producing a vaccine containing autologous antibodies |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009979 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009907 Nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for production |
| 01/15/2004 | US20040009180 Transdermal botulinum toxin compositions |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | CA2489396A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/14/2004 | EP1380576A1 Novel 1h-indazole compound |
| 01/14/2004 | EP1380573A2 Isoquinolines and preparation thereof |
| 01/14/2004 | EP1379873A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 01/14/2004 | EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |